Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/ refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis

A systematic review and meta-analysis on the treatment of relapsed/refractory hematologic malignancy in children and young adults investigates the potential benefits of allogeneic stem-cell transplantation (allo-SCT) following chimeric antigen receptor T-cell (CAR T-cell) therapy. Researchers analyzed 12 cohort studies, primarily focusing on B-cell acute lymphoblastic leukemia, to assess outcomes such as complete remission, survival, relapse, and mortality rates. Although the evidence level is currently low, the findings suggest that allo-SCT after CAR T-cell infusion may improve patient survival, highlighting the need for further clinical research.